Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts

Transplantation. 2016 Feb;100(2):325-333. doi: 10.1097/TP.0000000000000961.

Abstract

Background: Tacrolimus (Tac) and Cyclosporine A (CyA) calcineurin inhibitors (CNIs) are 2 effective immunosuppressants which are essential to prevent allograft rejection. Calcineurin inhibitors are known to be nephrotoxic. However, the precise mechanism of nephrotoxicity is not fully understood. In this study, we investigated the in vivo effects of CNIs on the local renal renin-angiotensin system in the collecting duct (CD).

Methods: Three-week-old mice were treated with either vehicle, CyA (2 mg/kg per day), Tac (0.075 mg/kg per day), CyA + Aliskiren (25 mg/kg per day), or Tac + Aliskiren for 3 weeks. Serum creatinine was measured. Renin and vascular endothelial growth factor (VEGF) contents in CD were evaluated with flow cytometry and multiphoton microscopy. The diameter of vessels was assessed with multiphoton microscopy, and the amount of renal collagen was determined by real-time polymerase chain reaction and Masson staining.

Results: The elevated level of serum creatinine in CNI groups was abolished by Aliskiren. Flow cytometric analysis found elevated renin content in principal cells, which was prevented by Aliskiren. This result was further confirmed with multiphoton microscopy. The VEGF content in CD correlated with reduced capillary diameter and with the formation of fibrotic islands.

Conclusions: Calcineurin inhibitors induce production of renin in the CD that may contribute to decreased renal blood flow. In turn, CD responds with increased VEGF production, resulting in disproportional vessel growth, further worsening the local hypoxia and striped fibrosis surrounding the CDs. Aliskiren, a direct renin inhibitor blocks these effects and improves CNI-induced nephropathy by decreasing renin production in the CDs. Our data suggest that Aliskiren may be used for the prevention of CNI nephrotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / pharmacology
  • Animals
  • Biomarkers / blood
  • Calcineurin Inhibitors*
  • Capillaries / metabolism
  • Capillaries / pathology
  • Collagen Type I / genetics
  • Collagen Type I / metabolism
  • Creatinine / blood
  • Cyclosporine*
  • Cytoprotection
  • Disease Models, Animal
  • Fibrosis
  • Flow Cytometry
  • Fumarates / pharmacology
  • Immunosuppressive Agents*
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / genetics
  • Kidney Diseases / metabolism
  • Kidney Diseases / pathology
  • Kidney Diseases / prevention & control
  • Kidney Tubules, Collecting / blood supply
  • Kidney Tubules, Collecting / drug effects*
  • Kidney Tubules, Collecting / metabolism
  • Kidney Tubules, Collecting / pathology
  • Male
  • Mice, Inbred C57BL
  • Microscopy, Fluorescence, Multiphoton
  • Real-Time Polymerase Chain Reaction
  • Renal Circulation
  • Renin / antagonists & inhibitors
  • Renin / metabolism*
  • Renin-Angiotensin System / drug effects*
  • Tacrolimus*
  • Time Factors
  • Up-Regulation
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • Amides
  • Biomarkers
  • Calcineurin Inhibitors
  • Collagen Type I
  • Fumarates
  • Immunosuppressive Agents
  • Vascular Endothelial Growth Factor A
  • vascular endothelial growth factor A, mouse
  • aliskiren
  • Cyclosporine
  • Creatinine
  • Renin
  • Tacrolimus